Suppr超能文献

相似文献

1
Immunogenetic Association Underlying Severe COVID-19.
Vaccines (Basel). 2020 Nov 20;8(4):700. doi: 10.3390/vaccines8040700.
2
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
3
Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19.
J Leukoc Biol. 2021 Jul;110(1):21-26. doi: 10.1002/JLB.5HI0720-466R. Epub 2021 Jan 19.
4
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.
Clinics (Sao Paulo). 2021 Apr 9;76:e2342. doi: 10.6061/clinics/2021/e2342. eCollection 2021.
9
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
J Endocrinol. 2020 Nov;247(2):R45-R62. doi: 10.1530/JOE-20-0260.

引用本文的文献

2
Exploring the interplay between host genetics and acute and long COVID: A narrative review.
Clinics (Sao Paulo). 2025 Jun 20;80:100708. doi: 10.1016/j.clinsp.2025.100708.
4
Healthcare Workers' Assessment of a Visual Triage System (VTS).
Cureus. 2023 Dec 4;15(12):e49910. doi: 10.7759/cureus.49910. eCollection 2023 Dec.
6
Severe COVID-19 multisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection.
Eur Respir Rev. 2023 Mar 8;32(167). doi: 10.1183/16000617.0197-2022. Print 2023 Mar 31.
7
Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study.
Biomedicines. 2023 Feb 10;11(2):516. doi: 10.3390/biomedicines11020516.
8
Effects of Epitranscriptomic RNA Modifications on the Catalytic Activity of the SARS-CoV-2 Replication Complex.
Chembiochem. 2023 Apr 17;24(8):e202300095. doi: 10.1002/cbic.202300095. Epub 2023 Mar 22.
10
Association Between Genetic Predictors for C-Reactive Protein and Venous Thromboembolism With Severe Adverse Coronavirus Disease 2019 Outcomes.
Crit Care Explor. 2021 Dec 20;3(12):e0602. doi: 10.1097/CCE.0000000000000602. eCollection 2021 Dec.

本文引用的文献

2
Genetic mechanisms of critical illness in COVID-19.
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
3
Human recombinant soluble ACE2 in severe COVID-19.
Lancet Respir Med. 2020 Nov;8(11):1154-1158. doi: 10.1016/S2213-2600(20)30418-5. Epub 2020 Sep 24.
4
Repurposing anticancer drugs for the management of COVID-19.
Eur J Cancer. 2020 Dec;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22.
5
COVID-19: Infection or Autoimmunity.
Front Immunol. 2020 Sep 11;11:2055. doi: 10.3389/fimmu.2020.02055. eCollection 2020.
7
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16.
8
The major genetic risk factor for severe COVID-19 is inherited from Neanderthals.
Nature. 2020 Nov;587(7835):610-612. doi: 10.1038/s41586-020-2818-3. Epub 2020 Sep 30.
9
Artificial intelligence in COVID-19 drug repurposing.
Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8. Epub 2020 Sep 18.
10
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验